<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02962999</url>
  </required_header>
  <id_info>
    <org_study_id>KCOPD1</org_study_id>
    <nct_id>NCT02962999</nct_id>
  </id_info>
  <brief_title>Effect Of Ketamine Infusion In Patients With COPD Applied One Lung Ventilation</brief_title>
  <official_title>Effect Of Ketamine Infusion On Oxygenation And Ventilation Mechanics In Patients With Chronic Obstructive Pulmonary Disease Applied One Lung Ventilation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cukurova University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cukurova University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic obstructive pulmonary disease (COPD) patients often undergo thoracic surgery due to
      lung cancer and emphysematous changes. One lung ventilation (OLV) used in thoracic surgery
      aggravates hypoxia and hypercapnia increasing intrapulmonary shunt and dead space.Ketamine
      provide bronchodilation by inhibiting the reuptake of catecholamines in the circulation. It
      also serves relaxation of bronchial smooth muscle. Our aim in this study, effects of ketamine
      on arterial oxygenation, the shunt fraction and the lung mechanics in patients with COPD who
      administered OLV because of thoracic surgery. Thirty patients with COPD who undergo
      thoracotomy for lung lobectomy will be included in this study. Patients will be randomly
      divided to a control group (%0,9 saline- CG) or a keta (ketamine- KG) group. KG will be
      administered 0,5 mg/kg/hour ketamine infusion after the induction, CG will be administered
      saline infusion. Peak airway pressure (Ppeak), plato airway pressure (Pplato), static
      compliance, shunt fraction and arteriel blood gas values (Pa02, PaC02) will be recorded
      before initiation of OLV and 30 minutes intervals after initiation of OLV.To evaluate the
      postoperative pulmonary complications, Pa02, PaC02 in blood gas and Pa02/Fi02 values will be
      recorded 20 minute after arrival at postoperative care unit. Patients will be evaluated for
      pneumonia, atelectasis and acute lung injury at postoperative 72 h and findings will be
      recorded. 30 day mortality will be recorded.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic obstructive pulmonary disease (COPD) is a risk factor for cardiopulmonary morbidity
      and mortality after thoracic surgery. The elastic recoil reduction and structural changes in
      the small airways and alveoli cause pulmonary air trapping and hyperinflation in patients
      with COPD. Chronic alveolar hypoxia results structural changes in the pulmonary arteriol such
      as medial hypertrophy and muscularization. Ventilation-perfusion mismatch and from the right
      to left shunt cause hypoxia in patients with COPD. COPD patients often undergo thoracic
      surgery due to lung cancer and emphysematous changes. One lung ventilation (OLV) used in
      thoracic surgery aggravates hypoxia and hypercapnia increasing intrpulmonary shunt and dead
      space. Positive end expirium pressure (PEEP) and alveolary recruitment are not applicable to
      treat hypoxia because of development of high intrinsic PEEP. Ketamine is an intravenous
      general anesthetic agent widely used for many years and has sympathomimetic bronchodilator
      features on the airway. Ketamine provide bronchodilation by inhibiting the reuptake of
      catecholamines in the circulation. It also serves relaxation of bronchial smooth muscle. Our
      aim in this study, effects of ketamine on arterial oxygenation, the shunt fraction and the
      lung mechanics in patients with COPD who administered OLV because of thoracic surgery. This
      prospective, randomized, double blinded, controlled study will be conducted following
      Cukurova University Faculty of Medicine Ethics Committee approval and written informed
      patient consent. Thirty patients who undergo thoracotomy for lung lobectomy will be included
      in this study.Patients will be monitored for electrocardiography (ECG), oxygen saturation
      (Sa02) and non-invasive blood pressure and applied thoracal (T 5-8) epidural catheter which
      will be used postoperative analgesia. After the induction of anesthesia, patients will be
      intubated with double lumen tube (DLT). The position of the DLT will be confirmed with
      fiberoptic bronchoscope. Anesthesia will be maintained with %4-6 desflurane and 0,025-0,05
      microgram/dk/min remifentanil. Desflurane will be titrated to maintain a bispectral index of
      40 to 60.Patients will be randomly divided to a control group (%0,9 saline- CG) or a keta
      (ketamine- KG) group. KG will be administered 0,5 mg/kg/hour ketamine infusion, CG will be
      administered saline infusion. Patients will be ventilated with volume controlled ventilation
      (VCV), tidal volume (TV) 8 mlt/kg and rate of inspirium:expirium (I:E)=1:2,5 during two lung
      ventilation. During OLV, the lungs were ventilated with VCV, TV 5 mlt/kg, I:E=1:2,5, PEEP=
      5cmH20. The fraction of inspired oxygen (Fi02) will initially set at 0,6. In cases of
      desaturation to Sa02 less than 95%, Fi02 will be increased by 0,2 up to 1,0. Peak airway
      pressure (Ppeak), plato airway pressure (Pplato), static compliance, shunt fraction and
      arteriel blood gas values (Pa02, PaC02) will be recorded before initiation of OLV and 30
      minutes intervals after initiation of OLV. To evaluate the postoperative pulmonary
      complications, Pa02, PaC02 in blood gas and Pa02/Fi02 values will be recorded 20 minute after
      and 1 hour after arrival at postoperative care unit. If the patient shows signs of dyspnea
      and Pa02/Fi02&lt;300, the patient will be admitted intensive care unit. Patients will be
      evaluated for pneumonia, atelectasis and acute lung injury at postoperative 72 h and findings
      will be recorded. 30 day mortality will be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Peak airway pressure (mmHg)</measure>
    <time_frame>From the start of OLV to end of OLV intraoperatively (before initiation of OLV and 30 minutes intervals up to 120 minutes after initiation of OLV)</time_frame>
    <description>Peak airway pressure (Ppeak-mmHg) will be recorded before initiation of OLV and 30 minutes intervals up to 120 minutes after initiation of OLV. Change from initiation of Ppeak at 120 minute will be evaluated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of arteriel P02</measure>
    <time_frame>From the start of OLV to postoperative 1 hour.(before initiation of OLV and 30 minutes intervals up to 120 minutes after initiation of OLV. Pa02 in blood gas values will be recorded 20 minute after arrival at postoperative care unit.</time_frame>
    <description>arteriel blood gas value (Pa02-mmHg) will be recorded before initiation of OLV and 30 minutes intervals up to 120 minutes after initiation of OLV and postoperative 1 hour. Pa02 in blood gas values will be recorded 20 minute after and 1 hour after arrival at postoperative care unit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Shunt fraction</measure>
    <time_frame>From the start of OLV to end of OLV intraoperatively (before initiation of OLV and 30 minutes intervals up to 120 minutes after initiation of OLV)</time_frame>
    <description>Shunt fraction will be calculated with; Qs/Qt= (5,8xRI)+6,7 RI= Respiratory index RI= (PA02-Pa02)/ Pa02 PA02= Alveolar 02 pressure PA02= ([PB-PH20]x Fi02)- PaC02 PB= Atmosphere pressure= 760 mmHg PH20= Water vapor pressure= 47 mmHg shunt fraction will be recorded before initiation of OLV and 30 minutes intervals up to 120 minutes after initiation OLV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Plato airway pressure (mmHg)</measure>
    <time_frame>From the start of OLV to end of OLV intraoperatively (before initiation of OLV and 30 minutes intervals up to 120 minutes after initiation of OLV)</time_frame>
    <description>Plato airway pressure (Pplato-mmHg) will be recorded before initiation of OLV and 30 minutes intervals up to 120 minutes after initiation of OLV. Change from initiation of Ppeak at 120 minute will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of arteriel PC02</measure>
    <time_frame>From the start of OLV to postoperative 1 hour.(before initiation of OLV and 30 minutes intervals up to 120 minutes after initiation of OLV. PaC02 in blood gas values will be recorded 20 minute after arrival at postoperative care unit.)</time_frame>
    <description>arteriel blood gas value (PaC02-mmHg) will be recorded before initiation of OLV and 30 minutes intervals up to 120 minutes after initiation of OLV and postoperative 1 hour. PaC02 in blood gas values will be recorded 20 minute after and 1 hour after arrival at postoperative care unit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease Mild</condition>
  <condition>Chronic Obstructive Pulmonary Disease Moderate</condition>
  <condition>Chronic Obstructive Pulmonary Disease Severe</condition>
  <condition>Lungcancer</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After induction, patients will be administered 0,5 mg/kg/hour ketamine infusion intraoperatively. Anesthesia will be maintained with %4-6 desflurane and 0,025-0,05 microgram/dk/min remifentanil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>After induction, patients will be administered saline infusion intraoperatively. Anesthesia will be maintained with %4-6 desflurane and 0,025-0,05 microgram/dk/min remifentanil.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>After induction, patients will be administered 0,5 mg/kg/hour ketamine infusion intraoperatively.</description>
    <arm_group_label>Ketamine</arm_group_label>
    <other_name>Ketalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>After induction, patients will be administered saline infusion intraoperatively.</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>%0,9 NaCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age more than 40 years

          -  American Society of Anesthesiologists' physical status 2-3

          -  Diagnosis of COPD

          -  Forced expiratory volume in 1 second (FEV1) ≥ %50 in a preoperative pulmonary function
             test.

        Exclusion Criteria:

          -  Heart failure

          -  Severe functional liver or kidney disease

          -  Pregnancy,

          -  Obesity (BMI≥30)

          -  Respiratory failure (Pa02&lt; 55 mmHg, PaC02&gt; 55 mmHg)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Feride Karacaer, Specialist</last_name>
    <role>Study Director</role>
    <affiliation>Çukurova University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Feride Karacaer, Specialist</last_name>
    <phone>+90322 3386060</phone>
    <phone_ext>3264</phone_ext>
    <email>feridekaracaer@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ebru Biricik, Specialist</last_name>
    <phone>+90322 3386060</phone>
    <phone_ext>3264</phone_ext>
    <email>ebrubiricik@mynet.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cukurova University</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feride Karacaer, Specialist</last_name>
      <phone>+90322 3386060</phone>
      <phone_ext>3264</phone_ext>
      <email>feridekaracaer@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Dilek Özcengiz, Professor</last_name>
      <phone>+90322 3386060</phone>
      <phone_ext>3289</phone_ext>
      <email>dilekozcengiz@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cukurova University Faculty of Medicine Research Hospital</name>
      <address>
        <city>Adana</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feride Karacaer, Specialist Dr</last_name>
      <phone>+903223386060</phone>
      <phone_ext>3289</phone_ext>
      <email>feridekaracaer@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yasemin Güneş, Professor</last_name>
      <phone>0322 338 6060</phone>
      <phone_ext>3289</phone_ext>
      <email>ygunes@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dilek Özcengiz, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Çağatay Küçükbingöz, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ebru Biricik, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Murat Ilgınel, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gökhan Tümgör, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mehmet Ağın, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Weinreich AI, Silvay G, Lumb PD. Continuous ketamine infusion for one-lung anaesthesia. Can Anaesth Soc J. 1980 Sep;27(5):485-90.</citation>
    <PMID>7448609</PMID>
  </reference>
  <reference>
    <citation>Rees DI, Gaines GY 3rd. One-lung anesthesia--a comparison of pulmonary gas exchange during anesthesia with ketamine or enflurane. Anesth Analg. 1984 May;63(5):521-5.</citation>
    <PMID>6711845</PMID>
  </reference>
  <reference>
    <citation>Lee SH, Kim N, Lee CY, Ban MG, Oh YJ. Effects of dexmedetomidine on oxygenation and lung mechanics in patients with moderate chronic obstructive pulmonary disease undergoing lung cancer surgery: A randomised double-blinded trial. Eur J Anaesthesiol. 2016 Apr;33(4):275-82. doi: 10.1097/EJA.0000000000000405.</citation>
    <PMID>26716866</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2016</study_first_submitted>
  <study_first_submitted_qc>November 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2016</study_first_posted>
  <last_update_submitted>July 24, 2017</last_update_submitted>
  <last_update_submitted_qc>July 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cukurova University</investigator_affiliation>
    <investigator_full_name>Feride Karacaer</investigator_full_name>
    <investigator_title>Specialist doctor</investigator_title>
  </responsible_party>
  <keyword>Ketamine</keyword>
  <keyword>One lung ventilation</keyword>
  <keyword>Chronic obstructive pulmonary disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

